|
Varicosity
|
0.010 |
Biomarker
|
disease |
BEFREE |
The varicose veins group had higher incidence rates than the control group for DVT (6.55 vs 1.23 per 1000 person-years [10 360 vs 1980 cases]; absolute risk difference [ARD], 5.32 [95% CI, 5.18-5.46]), for PE (0.48 for the varicose veins group vs 0.28 for the control group per 1000 person-years [793 vs 451 cases]; ARD, 0.20 [95% CI, 0.16-0.24]), and for PAD (10.73 for the varicose veins group vs 6.22 for the control group per 1000 person-years [16 615 vs 9709 cases]; ARD, 4.51 [95% CI, 4.31-4.71]).
|
29486040 |
2018 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Here, we provide mechanistic insight into MT1-MMP cytoplasmic tail binding protein 1 (MTCBP-1) with respect to invadopodia formation, matrix remodeling, and invasion by pancreatic tumor cells.
|
30487181 |
2019 |
|
SPONDYLOCARPOTARSAL SYNOSTOSIS SYNDROME
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Individuals with SCT had an increased risk of CKD (odds ratio [OR], 1.57 [95% CI, 1.34-1.84]; absolute risk difference [ARD], 7.6% [95% CI, 4.7%-10.8%]), incident CKD (OR, 1.79 [95% CI, 1.45-2.20]; ARD, 8.5% [95% CI, 5.1%-12.3%]), and decline in eGFR (OR, 1.32 [95% CI, 1.07-1.61]; ARD, 6.1% [95% CI, 1.4%-13.0%]) compared with noncarriers.
|
25393378 |
2014 |
|
Sickle Cell Trait
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Sickle cell trait was also associated with albuminuria (OR, 1.86 [95% CI, 1.49-2.31]; ARD, 12.6% [95% CI, 7.7%-17.7%]).
|
25393378 |
2014 |
|
Rheumatoid Arthritis
|
0.030 |
Biomarker
|
disease |
BEFREE |
CIGB-814, originally named as E18-3 APL1 or APL1 in preclinical experiments, is a novel therapeutic peptide candidate for Rheumatoid Arthritis (RA).
|
28595106 |
2017 |
|
Rheumatoid Arthritis
|
0.030 |
Biomarker
|
disease |
BEFREE |
APL-1 is an altered peptide ligand derived from a novel CD4 + T cell epitope of human heat-shock protein of 60 kDa (HSP60), an autoantigen involved in the pathogenesis of rheumatoid arthritis (RA).
|
27160252 |
2017 |
|
Rheumatoid Arthritis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the ability of APL-1 in inducing apoptosis in PBMCs from RA patients, who were classified as active or inactive according to their DAS28 score.
|
24177275 |
2013 |
|
Prostatic Neoplasms
|
0.310 |
AlteredExpression
|
group |
LHGDN |
Immunohistochemistry of prostate tumor tissue microarrays showed that benign regions expressed more ADI1 than tumors, suggesting a suppressive role for ADI1 in prostate cancer.
|
17786183 |
2007 |
|
Prostatic Neoplasms
|
0.310 |
Biomarker
|
group |
CTD_human |
Immunohistochemistry of prostate tumor tissue microarrays showed that benign regions expressed more ADI1 than tumors, suggesting a suppressive role for ADI1 in prostate cancer.
|
17786183 |
2007 |
|
Prostatic Neoplasms
|
0.310 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemistry of prostate tumor tissue microarrays showed that benign regions expressed more ADI1 than tumors, suggesting a suppressive role for ADI1 in prostate cancer.
|
17786183 |
2007 |
|
Prostate carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The 5'-methylthioadenosine (MTA) cycle-participating human acireductone dioxygenase 1 (ADI1) has been implicated as a tumor suppressor in prostate cancer, yet its role remains unclear in hepatocellular carcinoma (HCC).
|
30858354 |
2019 |
|
Prostate carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Collectively, these observations argue that ADI1 may check prostate cancer progression through apoptosis and that this activity does not require metal binding.
|
17786183 |
2007 |
|
Prostate carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
ARD-266 is capable of reducing the AR protein level by >95% in these AR+ prostate cancer cell lines and effectively reduces AR-regulated gene expression suppression.
|
31804827 |
2019 |
|
Prostate carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
ARD-69 is capable of reducing the AR protein level by >95% in these prostate cancer cell lines and effectively suppressing AR-regulated gene expression.
|
30629437 |
2019 |
|
Presenile dementia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that a relative excess of nonsynonymous mutations in MTND genes in supercluster JTWIX is associated with an increased risk of PD and the disease progression to dementia.
|
15108120 |
2004 |
|
polyps
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Among 615 patients (66.9%) with a proximal large polyp, the risk of bleeding in the clip group was 3.3% and in the control group was 9.6% (ARD 6.3%; 95% CI 2.5%-10.1%); among patients with a distal large polyp, the risks were 4.0% in the clip group and 1.4% in the control group (ARD -2.6%; 95% CI -6.3% to -1.1%).
|
30885778 |
2019 |
|
Peripheral Arterial Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
The varicose veins group had higher incidence rates than the control group for DVT (6.55 vs 1.23 per 1000 person-years [10 360 vs 1980 cases]; absolute risk difference [ARD], 5.32 [95% CI, 5.18-5.46]), for PE (0.48 for the varicose veins group vs 0.28 for the control group per 1000 person-years [793 vs 451 cases]; ARD, 0.20 [95% CI, 0.16-0.24]), and for PAD (10.73 for the varicose veins group vs 6.22 for the control group per 1000 person-years [16 615 vs 9709 cases]; ARD, 4.51 [95% CI, 4.31-4.71]).
|
29486040 |
2018 |
|
Parkinson Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that a relative excess of nonsynonymous mutations in MTND genes in supercluster JTWIX is associated with an increased risk of PD and the disease progression to dementia.
|
15108120 |
2004 |
|
Pancreatic Neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Further, we observe an inverse correlation between MTCBP-1 and MT1-MMP expression both in cultured cell lines and human pancreatic tumors.
|
30487181 |
2019 |
|
Optic Atrophy, Hereditary, Leber
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Here, we define an X-chromosomal haplotype that interacts with specific MTND mutations to cause visual failure in the most common mtDNA disease, Leber hereditary optic neuropathy.
|
16380918 |
2005 |
|
Nicotinamide adenine dinucleotide coenzyme Q reductase deficiency
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
These findings demonstrate that mutations in MTND genes are relatively frequent in patients with complex I deficiency.
|
16044424 |
2005 |
|
Nephrolithiasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Supplementation using vitamin D with calcium was associated with an increased incidence of kidney stones (3 RCTs [n = 39 213]; pooled ARD, 0.33% [95% CI, 0.06% to 0.60%]), but supplementation with calcium alone was not associated with an increased risk (3 RCTs [n = 1259]; pooled ARD, 0.00% [95% CI, -0.87% to 0.87%]).
|
29677308 |
2018 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
A single dose of ARD-69 effectively reduces the level of AR protein in xenograft tumor tissue in mice.
|
30629437 |
2019 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The 5'-methylthioadenosine (MTA) cycle-participating human acireductone dioxygenase 1 (ADI1) has been implicated as a tumor suppressor in prostate cancer, yet its role remains unclear in hepatocellular carcinoma (HCC).
|
30858354 |
2019 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemistry of prostate tumor tissue microarrays showed that benign regions expressed more ADI1 than tumors, suggesting a suppressive role for ADI1 in prostate cancer.
|
17786183 |
2007 |